Ulcerative colitis
Conditions
Interventions
Experimental group:Oral mesalazine sustained-release granules combined with improved formula of Tounong San
Control group:Oral mesalazine sustained-release granules
Sponsors
Chengdu Hospital of Integrated Traditional Chinese and Western Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Meet the diagnostic criteria for mild to moderate ulcerative colitis as per the "Consensus Opinions on the Diagnosis and Treatment of Inflammatory Bowel Disease (2018 Beijing)" 2) Refer to the "Guidelines for Clinical Research of New Traditional Chinese Medicines" to formulate the Qi Deficiency and Blood Stasis type of ulcerative colitis 3) Aged =18 years and not exceeding 75 years 4) The subject (including male subjects) or their spouse/partner has no pregnancy plans in the next 12 months 5) Good communication skills and no allergic reactions to the drugs used in this study 6) Voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1) Patients with severe ulcerative colitis; 2) Those currently using other traditional Chinese medicines; 3) Pregnant or breastfeeding subjects; 4) Subjects who have used immunosuppressants in the past 6 months of treatment; 5) Subjects with severe complications such as localized intestinal stricture intestinal obstruction intestinal perforation toxic megacolon colon cancer etc.; 6) Ulcerative colitis accompanied by primary diseases such as cardiovascular cerebrovascular liver kidney or blood diseases; 7) Those intolerant to colonoscopy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| calprotectin;colorectal endoscopy; | — |
Secondary
| Measure | Time frame |
|---|---|
| C-reactive protein;Interleukin-1ß;hemoglobin;erythrocyte sedimentation rate;Interleukin-10S;TNF-a; | — |
Countries
China
Contacts
Public ContactXudong Wen
Chengdu Hospital of Integrated TCM and Western Medicine
Outcome results
None listed